This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ICAD Announces More Than 1,000 Early Stage Breast Cancer Patients Treated With Intraoperative Radiation Therapy (IORT) Using The Xoft System

iCAD, Inc. (Nasdaq: ICAD), a leading provider of advanced image analysis and radiation therapy solutions for the early identification and treatment of cancer, today announced at the 31 st Annual Miami Breast Cancer Conference that more than 1,000 early stage breast cancer patients have been treated with Intraoperative Radiation Therapy (IORT) using the Xoft® Axxent® Electronic Brachytherapy System®. With IORT, a full course of radiation therapy is delivered to the patient in the operating room immediately following lumpectomy, replacing six to eight weeks of daily traditional radiation.

“The growing adoption and utilization of the Xoft System further validates that IORT is an attractive alternative for the treatment of early stage breast cancer because of its compelling benefits to patients,” said Ken Ferry, President and CEO of iCAD. “By offering IORT with the Xoft System, hospitals are able to expand their comprehensive breast care programs by providing appropriate patients with the option to complete a full dose of radiation therapy in a single treatment.”

“The Xoft System provides patients with a treatment option that helps mitigate the logistical burdens often associated with a traditional course of radiation treatment,” said Barbara Schwartzberg, M.D., Director of Breast Services, Sarah Cannon/HealthONE, Rose Medical Center. “IORT with the Xoft System delivers radiation directly into the tumor cavity while the patient is still under anesthesia, minimizing radiation exposure to surrounding healthy tissue. Because the treatment is delivered in one dose, my patients are able to maintain their quality of life and return to their jobs and families quickly.”

A post-market, prospective, multi-center, clinical trial evaluating the safety, efficacy and cosmetic outcomes associated with IORT for early-stage breast cancer with the Xoft System is currently underway at hospitals across the U.S.

iCAD to Host Lunch Symposium during Miami Breast Cancer ConferenceOn March 8, 2014, iCAD will host the Breast IORT Symposium: Clinical and Practice Perspectives from 1:00 p.m. EST – 2:15 p.m. EST at the Fontainebleau Miami Beach Hotel during the 31 st Annual Miami Breast Cancer Conference taking place March 6 – March 9, 2014. Leading breast cancer surgeons will present and discuss their IORT clinical experience, which includes more than 400 patients. Topics will include IORT techniques, clinical advancements, scientific evidence, case review and IORT study protocol. The event is open to all conference attendees and the public. For more details or to register, please visit: http://www.xoftinc.com/IORTsymposiumreg.html.

iCAD will also showcase the Xoft System during the Miami Breast Cancer Conference at Booth #22.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs